Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Peripheral arterial disease (PAD) is the most common manifestation of systemic
atherosclerosis and accounts for significant morbidity and mortality among end-stage renal
disease (ESRD) patients. However, few studies have identified the prevalence and clinical
impact of PAD in this specific population.
Objectives: To perform a single-blinded parallel, controlled trial to examine the effect of
cilostazol treatment on plasma VEGF levels, tissue factors , inflammatory markers (such as
IL-6, hsCRP) levels, oxidative stress markers in ESRD patients with PAD Material and methods
Fourty HD patients on maintenance HD for > 3months were enrolled in this prospective,
single-blinded, randomized study. These patients were randomly allocated into 2 arms. After
baseline assessment, patients in the treatment arm received 12 weeks of added on therapy with
cilostazol 100mg/day. Blood pressure, heart rate, oxidative stress (malonyldialdehyde,
protein carbonyl and ADMA), inflammatory markers (hsCRP, IL-6) and plasma, VEGF and tissue
factors levels were measured before and after treatment.